Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

  • M. Saleh
  • , M. Barve
  • , V. Subbiah
  • , K. P. Papadopoulos
  • , D. Morgensztern
  • , N. B. Mettu
  • , S. Roychowdhury
  • , I. Spanggaard
  • , M. L. Veronese
  • , C. Tian
  • , I. M. Silverman
  • , M. Gutierrez

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science